Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT06101199 |
| Other study ID # |
iRISID-2023-1796 |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
October 16, 2023 |
| Est. completion date |
September 2026 |
Study information
| Verified date |
October 2023 |
| Source |
Thomas Jefferson University |
| Contact |
Jayakrishnan Nair, PT, MSPT, PhD |
| Phone |
352-871-5888 |
| Email |
Jayakrishnan.Nair[@]jefferson.edu |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
The goal of this clinical trial is to determine whether people with paralysis due to a spinal
cord injury can benefit from breathing short intermittent bouts of air with low oxygen (O2)
combined with slightly higher levels of carbon dioxide (CO2), interspaced by breathing room
air. The technical name for this therapeutic air mixture is 'acute intermittent
hypercapnic-hypoxia,' abbreviated as AIHH. Following exposure to the gas mixture,
participants will receive non-invasive electrical stimulation to the spinal cord paired with
specific and targeted exercise training.
The main question this trial aims to answer is: Can the therapeutic application of AIHH,
combined with non-invasive electrical stimulation to the spinal cord plus exercise training,
increase the strength of muscles involved in breathing and hand function in people with
paralysis due to a spinal cord injury?
Participants will be asked to attend a minimum of five study visits, each separated by at
least a week. During these visits, participants will be required to:
- Answer basic questions about their health
- Receive exposure to the therapeutic air mixture (AIHH)
- Undergo non-invasive spinal electrical stimulation
- Complete functional breathing and arm strength testing
- Undergo a single blood draw
- Provide a saliva sample
Researchers will compare the results of individuals without a spinal cord injury to those of
individuals with a spinal cord injury to determine if the effects are similar.
Description:
The objective of this proposal is to test the precision and effectiveness of combining
application of AIHH exposure with tSCS to prime response to task specific training in chronic
SCI, by pursuing the following specific aims:
Aim 1: To test the hypothesis that combining single session AHH with tSCS paired respiratory
strength training will synergistically induce greater respiratory motor output in chronic
SCI, than any treatment alone.
Rationale. Respiratory phase dependent activation of spinal circuits requires brainstem
neural drive. Therefore, augmenting descending drive with AIHH while lowering activation
threshold for spinal neuronal circuity with tSCS will have synergistic effect.
Aim 2: To test the hypothesis that combining single session AHH with tSCS paired upper
extremity strength training will synergistically induce greater upper extremity motor output
in chronic SCI, than any treatment alone.
Rationale. Precision upper extremity function require direct corticospinal innervation and
afferent feedback. Therefore, augmenting descending drive with AIHH and lowering activation
threshold for afferents with tSCS will have synergistic effect.
Aim 3: To identify biomarkers associated with diminished response to combinatorial AIHH with
tSCS paired functional strength training in chronic SCI.
Rationale. Presence of single nucleotide polymorphism (SNP) in genes involved in
neuroplasticity related cell signaling, will undermine treatment response.
Experimental Procedures
The Study will involve a total of 5 visits, each lasting for ~3 hours. First visit will be
clinical assessment followed by 4 experimental exposure and testing visits.
Clinical assessments. In addition to the clinical assessments conducted during in-person
screening, assessments will be conducted to comprehensively characterize each individual's
clinical presentation and SCI, and to determine initial status to monitor safety and
responses to study procedures. Standardized clinical tests will be used to assess spasticity,
neuropathic and chronic pain, vital signs and presence and severity of sleep-disordered
breathing. Specifically, the International Standards for the Neurological Classification of
Spinal Cord Injury will be used to assess segmental sensory and motor function and determine
injury characteristics (Kirshblum et al., 2011). Spasticity will be assessed using the Spinal
Cord Assessment Tool for Spastic Reflexes (SCATS), an objective and reliable measure of
clonic, extensor, and flexor spasms (Benz et al., 2005). The Neuropathic Pain Questionnaire
Short Form (Backonja & Krause, 2003) will be used to assess neuropathic pain and the Brief
Pain Inventory, a validated self-report assessment of pain severity and its impact on
function, will be used to assess and monitor pain (Keller, 2004). Vital signs including heart
rate and blood pressure will be assessed and baseline measures will be used to monitor safety
and evaluate responses to study procedures and to assess abnormal autonomic responses such as
autonomic dysreflexia. Since caffeine and nicotine alter cardiopulmonary function and may
influence responses to study interventions, participants will be asked to refrain from
consumption of caffeinated beverages and use of nicotine (e.g., tobacco products and
electronic cigarettes) for a minimum of 2 hours prior to participation in study procedures
(Turnbull et al., 2017; Hernandez-Lopez et al., 2013; Navarrete-Opazo et al., 2017a).
Participants will be asked to self-report caffeine and nicotine use as part of the monitoring
procedures (along with changes in pain, spasticity, medications, etc.). We considered more
rigid limitations on the use of these substances and concluded that recruitment and retention
would be negatively impacted if participants were excluded or expected to abstain from the
use of these common products. Participants will self-report their risk of sleep disordered
breathing (i.e., sleep apnea) using the validated Berlin Questionnaire (Chung et al., 2008).
Sleep apnea and sleep disordered breathing are highly prevalent in individuals with chronic
SCI, which may influence AIH effects (Sankari et al., 2014; Mateika and Syed, 2013; Vivodtzev
et al., 2020). As a note, it is not practical to exclude those with sleep apnea since recent
estimates indicate that nearly 80% of those with cervical SCI and more than 50% of those with
thoracic SCI experience at least some level of sleep disordered breathing (Sankari et al.,
2014). Indeed, sleep apnea appears to actually enhance the efficacy of AIH-therapy in people
with SCI (Vivodtzev et al., 2020). Overall, these clinical assessments will allow us to
comprehensively characterize study participants and describe features of our study
population. Detailed clinical characterization also will enable us to closely monitor
participants for safety and adverse responses.
Following completion of the initial paperwork and the clinical assessments, the participants
biospecimen will be (saliva and blood) will be collected.
Passive drool saliva. Saliva sample will be collected once on the day 1 of combinatorial
treatment session. Participants will be asked to only drink water and rinse their mouth with
water 10 minutes before collection of saliva. The participants will then be asked to pool
saliva in their mouth and deposit 2 ml of saliva into a sterile DNAase/RNAase free saliva
collection tube. The saliva will be frozen and stored at -20 C, immediately after collection.
Saliva specimens will list the subject's coded ID , date of specimen collection and the study
IRB number. Subsequently, the specimen will be transported to and stored at -80 C at the Jay
Nair Research Laboratory, Jefferson Alumni Hall where it will be analyzed by study
investigator, Dr. Jay Nair. Saliva samples will be thawed and centrifuged for analysis. Once
the study is complete, the remaining sample will be destroyed by pouring 10% bleach solution
into the sample. The bleached sample will be poured down the laboratory drain and discarded.
After biomarker sample collection and preliminary safety testing outlined above, we will
proceed with experimental procedures at the Jefferson Rehabilitation Institute research
laboratory. In random order, the participant will either receive AIIH/Sham exposure, a 20
minutes of break followed by tSCS paired with respiratory strength training (Study 1) or
functional upper extremity training (Study 2). The remaining arm of Study 1/Study 2
experiment will be performed after a minimum 1 week washout period.
Similarly, the participant will receive either AIIH/Sham exposure, a 20 minutes of break
followed by tSCS paired with upper extremity functional training (Study 2). The remaining arm
of Study 2 experiment will be performed after a minimum 1 week washout period.
Neurophysiology
Study 1 Surface electromyography (EMG). Costal diaphragm, external intercostal,
sternocleidomastoid muscle activity will be recorded during quiet breathing and maximal
inspiratory efforts using a surface electrode placed in the 7th or 8th intercostal space on
the midclavicular line. Signals will be amplified (x 200) and band-pass filtered (0.1-3 kHz;
Model 78D, Grass Instruments; Oakville, ON, Canada), sampled at 10 kHz (PowerLab 16SP, AD
Instruments; Colorado Springs, CO, USA), and monitored online using LabChart software (AD
Instruments; Colorado Springs, CO, USA) [9] [10].
Study 2 Surface EMG: First dorsal interosseous EMG (FDI): to record electrical activity from
the upper extremity muscle, self-adhesive surface electrodes will be placed on the dominant
side FDI secured to the skin in a muscle tendon with one electrode placed over the belly of
the muscle (~3 cm apart). The electrodes and amplifiers used will be same as above.
The ground electrode is placed on the acromion process of the scapula or the anterior
superior iliac spine of the pelvis. The skin is cleaned prior to electrode placement using
conductive gel to minimize electrical impedance. This may include shaving the area of skin
where electrodes will be placed.
Transcranial Magnetic Stimulation
Study 1: Diaphragm motor evoked potentials: Subjects will be seated comfortably, fully
supported with the neck slightly flexed. Transcranial magnetic stimulation is performed
according to the technique described by [11]. The vertex of the skull is identified by the
intersection between nasion to inion and tragus to tragus. The region of the cortex
responsible for diaphragm motor activation is located approximately 3 cm lateral and 2 cm
anterior to the vertex. Single-pulse (1 Hz) stimuli are delivered using a handheld 70-mm
figure-of-eight coil powered by a magnetic stimulator. The coil is held over the left
hemisphere of the brain with current flowing in the anteroposterior direction. The coil is
then moved slightly from the pre-determined site and rotated in 45° instalments until the
largest MEP is observed. This location is marked on a tight-fitting swimming cap placed over
the subject's head to ensure accurate coil positioning in future stimulations.
Study 2: FDI motor evoked potentials: Subjects will be seated comfortably for stimulation.
The optimal position for eliciting a motor evoked potantial in the FDI muscle (hot spot) is
determined by moving the coil, with the handle pointing backward and 45° away from the
midline, in small steps along the hand representation of the primary motor cortex.
Single-pulse (1 Hz) stimuli are delivered using a handheld 70-mm figure-of-eight coil powered
by a magnetic stimulator. The coil is held over the dominant side hemisphere of the brain
with current flowing in the anteroposterior direction. The hot spot is defined as the region
where the largest MEP in the FDI could be evoked with the minimum intensity (Rothwell et al.,
1999). This location is marked on a tight-fitting swimming cap placed over the subject's head
to ensure accurate coil positioning in future stimulations.
Cervical Magnetic Stimulation.
For Study 1 and 2 the location for CMS stimulation is same. This will be done according to
the technique described by [12]. Single-pulse (1 Hz) stimuli will be delivered using a 90-mm
handheld circular coil placed over the cervical spine (C3-C7). Recruitment curves are plotted
by gradually increasing the intensity of stimulus from 40 to 100% of the maximal stimulator
output in 5% increments. Approximately 3-10 stimulations will be performed at each intensity
separated by 10-30 seconds. If the subject wishes to take an extended break between
stimulations, they may do so until ready to continue. Single-pulse (1 Hz) stimulation is very
safe even at the highest stimulator outputs [13]. If the subject wishes to take an extended
break between stimulations, they may do so until ready to continue. As with all procedures,
participants will be closely monitored for any discomfort. Recruitment curves for CMS will be
plotted but starting at 60% stimulation intensity. During these stimulation procedures we
will closely monitor the subject for discomfort and they are encouraged to inform the
experimenter if they wish for testing to pause and take a break, or if they no longer wish
for stimulations to occur.
Ventilation (Study 1 and 2)
After we have performed the baseline stimulations (CMS and TMS), we will record breathing
frequency, tidal volume, minute ventilation and inspired/expired gas concentrations during
normal resting breathing for a period of 5-10 minutes. These measures will continue
throughout AIHH/Sham exposure and for up to 1 hour after.
Functional Assessments
Respiratory assessments (Study 1)
After study enrollment, baseline respiratory function will be assessed at two time points
prior to the intervention: 1) during participant screening, and 2) on Day 1 (pre-test) of
each intervention (AIHH/Sham + tSCS paired respiratory strength training). This approach will
ensure a valid initial assessment and minimize the influence of motor learning on outcomes
(Larson et al., 1993). Subsequent (post) tests of respiratory function will be conducted on
Days 1, 3 and 7 post-intervention. For each intervention, we will calculate the initial
effect, as measured as the change in function from pre-test to post-test. The post-testing
schedule ensures we are able to quantify sustained changes following each intervention (or
sham) protocol. Respiratory tests will be conducted in a randomized order and a minimum of 3
trials of each test will be performed with rest intervals between trials. Tests will be
conducted at approximately the same time of day and in a consistent, seated position (Terson
de Paleville et al., 2014). All testing will be performed in accordance with the American
Thoracic Society testing guidelines (ATS, 2002) and values will be adjusted for individuals
with SCI (Kelley et al., 2003). Our research team has expertise with clinical respiratory
testing and these are routine measurements at Brooks Rehabilitation.
Maximal inspiratory and expiratory pressures are the primary study outcomes. Inspiratory
pressure generation is indicative of inspiratory strength and is associated with pulmonary
health and infection risk (Raab et al., 2016; Postma et al., 2013; Stolzmann et al., 2008).
Expiratory pressure generation is reflective of expiratory respiratory strength and is
associated with airway clearance and cough (Park et al., 2010). Inspiratory and expiratory
pressure generation improve following weeks of respiratory strength training and following
single-day sessions of AIH (Roth et al., 2010; Mueller et al., 2012; Ahmed et al., 2017;
Sutor et al., 2021). Measurements will be obtained using a mouthpiece attached to the
pneumotach (Hans Rudolph, Shawnee, KS, USA) to measure indices of ventilation and use of
nasal clips. To obtain maximal inspiratory pressure, participants will exhale to residual
volume and attempt a maximal inspiration for at least 2 seconds with occluded inspired line.
Maximal expiratory pressure will be measured with forced expiration against occluded expired
line after the participant inhales to near total lung capacity (ATS, 2002).
Forced vital capacity is the volume of air displaced during a forced expiration to residual
volume, following a full inspiration to total lung capacity. Forced vital capacity will be
measured using a mouthpiece attached to the pneumotach (Hans Rudolph, Shawnee, KS, USA) and
use of nasal clips. The signal will be recorded using Powerlab (AD Instruments; Colorado
Springs, CO, USA). A minimum of three acceptable flow-volume curves will be recorded.
Impairments in pulmonary function are associated with higher risks of respiratory illness and
higher mortality rate (Postma et al., 2009; Stolzmann et al., 2010).
Airway occlusion pressure (P0.1) is the pressure generated at the mouth in the first 0.1
second of inspiration, when the airway is unexpectedly occluded at the end of an expiration.
The negative pressure generation in 0.1 seconds reflects respiratory motor drive without time
for modification by sensory systems (lung stretch, visual, etc.). In essence, the P0.1
reflects the spontaneous (automatic) functional activity of inspiratory muscles at rest.
Mouth occlusion pressure at this time is often regarded as an index of inspiratory
neuromuscular drive (Whitelaw and Derenne, 1993). This measure will be obtained while
participants breathe through a mouthpiece connected to a 2-way valve in a closed circuit. The
inspiratory valve will be occluded without participant awareness during expiration and
maintained until the subsequent inspiratory effort. Negative pressure generation will be
recorded using a pressure transducer connected to the heated pneumotach (Hans Rudolph,
Shawnee, KS, USA); a minimum of 6-7 recordings will be obtained and averaged.
Upper extremity functional assessment (Study 2)[JN1]
We will use Box and Blocks and the Grip Release Test to assess hand function. For functional
task practice we will use the Edee Field-Fote protocol.
Experimental Intervention
Acute Intermittent Hypercapnic Hypoxia/Sham Exposure for Study 1 and 2
After baseline recordings have been made (magnetic stimulation and resting ventilation for
Study 1 and upper extremity functional testing for Study 2), the subject will be positioned
for the delivery of AIHH/Sham in both studies. The subject will be seated comfortably with
the back and head supported. The experimental air is delivered through a facemask attached to
a reservoir bag with the predetermined fractions of inspired oxygen and carbon dioxide. For
Acute intermittent hypoxia with hypercapnia (target fraction of inspired oxygen [FIO2] =
0.09; target fraction of inspired carbon dioxide [FICO2] = 0.04). A total of 15 hypoxic and
hypercapnic episodes will be delivered, each lasting 60 seconds in duration and separated by
90 seconds of breathing room air. For Sham air exposure the participant will be breathing
room air for the same duration of time. Subjects will be asked if they feel alright every few
minutes during the protocol and cardiovascular vital signs (heart rate, blood pressure and
oxygen saturation) will be monitored throughout. Ventilatory parameters outlined above will
also be monitored.
Cardiovascular Monitoring for both Study 1 and 2
Oxyhemoglobin saturation (SpO2) is measured continuously during AIH using non-invasive finger
pulse oximetry. Heart rate (HR) and blood pressure (BP) are monitored during baseline tidal
breathing and once every 2-3 stages into the AIH trial using an automated sphygmomanometer.
If SpO2 drops below 80% during a hypoxic dose, the inspired O2 will be raised until SpO2
levels are ≥80%. It is not expected that HR or BP will rise excessively (HR < 100 bpm; BP <
160/100) during AIH. Prior studies using AIH have reported no adverse responses to AIH and
that most participants cannot distinguish between breathing the short bouts of lower oxygen
and room air [14, 15]. Only once vital signs have returned to normal following the AIH
protocol, will we continue the experiment.
tSCS paired Respiratory strength training (Study 1)
tSCS paired respiratory strength training for Study 1 will be conducted 20 minutes following
the AIHH or Sham treatment. A closed loop stimulation parameter will be used to pair with
respiratory strength training. In a closed loop stimulation the parameters are continuously
updated in real-time, based upon the exact movement state of the person in that moment. The
stimulation will be applied simultaneously with respiratory strength training guided by a
team of trained occupational and physical therapists. Respiratory strength training will be
conducted using a using a standard, spring-loaded threshold device (Respironics Inc,
Murrysville, PA, USA). The spring can be adjusted to modify the pressure required to open the
valve, and the device is reversible for use with both inspiratory and expiratory training.
The hand-held device is readily available and commonly used in clinical practice.
Participants will complete 1 warm-up set at a pressure threshold approximately 40% of their
pre-test outcomes (obtained on the same day) for maximal inspiratory and expiratory pressure
generation. Following warm-up, participants will train at pressure threshold approximately
70% of their pre-test outcomes and will include three sets of 6-12 repetitions for both
inspiratory and expiratory strength training. A training breath will consist of a ~1-2-second
sustained effort through the device, separated by 5-10 seconds of quiet breathing. This
format of AIH followed by task-specific training has been successfully applied in prior
studies (Hayes et al., 2014; Ahmed et al., 2017), and enables sufficient time to increase
BDNF following AIH or AIHH, thereby augmenting the impact of task-specific training
(Baker-Herman et al., 2004; Lovett-Barr et al., 2012; Welch et al., 2020).
tSCS paired Upper limb functional training (Study 2)
tSCS paired upper limb functional training for Study 2 will be conducted 20 minutes following
the AIHH or Sham treatment. A closed loop stimulation parameter will be used to pair with
upper limb functional training. In a closed loop stimulation the parameters are continuously
updated in real-time, based upon the exact movement state of the person in that moment. The
stimulation will be applied simultaneously with upper limb functional training guided by a
team of trained occupational and physical therapists. tSCS paired upper limb functional
training sessions will be ~1 hour duration. Training may include upper extremity training of
large and small movements, games, and large and small object manipulation. Upper extremity
FTP may include repetitions of reaching, grasping, and manipulation actions.
Washout period. A 1-week washout period will occur between each single session intervention
to minimize carry-over effects. The duration of this washout period is based on human data
suggesting that effect of single session AIH study could no longer be detected one week later
(Sutor et al., 2021). The washout duration was balanced against experiences with factors
impacting participant retention, such as participant engagement, scheduling difficulties that
mount with longer time delays, and researcher-participant-clinician partnerships. Based on
the need to balance these opposing considerations, we sought a balance between longer
washouts that enable plasticity to wane while minimizing the risk of losing participants and
disrupting our cross-over design.
Post-Testing Study 1 and 2
Ventilation will continue to be recorded for 1 hour post AHH exposure for both Study 1 and 2
for monitoring safety.
Poste Neurophysiology Assessment: Approximately 30 minutes after the AIH/Sham exposure and
tSCS paired respiratory training for Study 1, and upper extremity training for Study 2, we
will perform another round stimulation. The procedures outlined above for CMS and TMS will be
followed for post testing on diaphragm muscle (study 1) and FDS muscle (study2). This
includes producing recruitment curves where the intensity of the stimulus is gradually
increased from 40-100% for CMS and 60-100% for TMS in 5% increments. Approximately 3-10
stimulations will be performed at each intensity separated by 10-30 seconds. Subjects may
take an extended break at any time during testing if they experience discomfort.
Post Functional Assessment: Soon after the neurophysiology test the participant will undergo
functional tests as outlined above. For Study 1, respiratory functional assessment and for
Study 2 upper extremity functional testing will be performed.
c. Data analysis: Provide the methods by which the study objectives/aims will be assessed or
measured, i.e., statistical analysis plan, qualitative research methods such as procedures
for conducting theme analysis and enhancing validity, program evaluation methods and analysis
plan, or mixed methods analysis plan. For a quantitative study, include what statistical
tools will be applied and how the study is powered, if appropriate. Pilot studies do not
require a statistical plan but need to outline how the results will be used to power future
studies.
To test Specific aim 1, that is "combining single session AHH with tSCS paired respiratory
strength training will synergistically induce greater respiratory motor output in chronic
SCI, than any treatment alone"; we will quantify and compare the % change from baseline in
the cardio-respiratory outcome measures. Evoked diaphragmatic potentials will be analyzed for
latency (difference in time between stimulus artifact and evoked response onset), duration
(difference in time between evoked response onset and offset), amplitude (difference between
positive and negative peaks), and area (total area of rectified EMG). Central motor
conduction time is calculated as the difference between latency of TMS and CMS evoked
potentials. We will compare the treatment difference in ventilatory, cardiorespiratory
parameters between AIHH vs Sham exposure paired combinatorial treatment.
To test Hypothesis 2, that "combining single session AHH with tSCS paired upper extremity
strength training will synergistically induce greater upper extremity motor output in chronic
SCI, than any treatment alone"; we will quantify and compare the % change from baseline in
the upper extremity neurophysiology and functional outcome measures. % change from baseline
for first dorsal interosseous finger potentials will be analyzed for latency (difference in
time between stimulus artifact and evoked response onset), duration (difference in time
between evoked response onset and offset), amplitude (difference between positive and
negative peaks), and area (total area of rectified EMG). Central motor conduction time is
calculated as the difference between latency of TMS and CMS evoked potentials. A
quantification of the participant's upper extremity function with a battery of standardized
functional tests will also be performed.
To test Hypothesis 3, that "presence of subclinical inflammation and/or dysfunctional single
nucleotide polymorphism in genes regulating neuroplasticity, will diminish motor response to
treatment"; we will classify the participants based on the presence of subclinical
inflammation and/ or dysfunctional single nucleotide polymorphism in genes linked with
neuroplasticity.
Power calculation: Our power calculation is based on prior data in use of AIHH in healthy
humans and difference in the diaphragm motor evoked potentials with respect to sham air.
Assuming a type I error rate of 0.05, a treatment difference of 30%, and the corresponding
standard deviation of 41, we have 80% power to detect the treatment improvement of AIHH over
sham exposure given a sample size of 29. Given that in this study a combinatorial treatment
approach and no preliminary data is available for power estimation, we assume that a sample
size of 29 participants with chronic SCI will be sufficiently powered for the experiment
[JN1]What is currently being used in the study for functional evaluation can be used here as
well.
Data analysis
Provide statistical design for primary endpoint only. Please indicate how the study is
powered and what statistical tool(s) will be applied:
Note: Please do not cut and paste entire statistical section from the sponsor protocol. Pilot
studies do not require a statistical plan but need to outline how the results will be used to
power future studies.) To test Specific aim 1, that is "combining single session AHH with
tSCS paired respiratory strength training will synergistically induce greater respiratory
motor output in chronic SCI, than any treatment alone"; we will quantify and compare the %
change from baseline in the cardio-respiratory outcome measures. Evoked diaphragmatic
potentials will be analyzed for latency (difference in time between stimulus artifact and
evoked response onset), duration (difference in time between evoked response onset and
offset), amplitude (difference between positive and negative peaks), and area (total area of
rectified EMG). Central motor conduction time is calculated as the difference between latency
of TMS and CMS evoked potentials. We will compare the treatment difference in ventilatory,
cardiorespiratory parameters between AIHH vs Sham exposure paired combinatorial treatment.
To test Hypothesis 2, that "combining single session AHH with tSCS paired upper extremity
strength training will synergistically induce greater upper extremity motor output in chronic
SCI, than any treatment alone"; we will quantify and compare the % change from baseline in
the upper extremity neurophysiology and functional outcome measures. % change from baseline
for first dorsal interosseous finger potentials will be analyzed for latency (difference in
time between stimulus artifact and evoked response onset), duration (difference in time
between evoked response onset and offset), amplitude (difference between positive and
negative peaks), and area (total area of rectified EMG). Central motor conduction time is
calculated as the difference between latency of TMS and CMS evoked potentials. A
quantification of the participant's upper extremity function with a battery of standardized
functional tests will also be performed.
To test Hypothesis 3, that "presence of subclinical inflammation and/or dysfunctional single
nucleotide polymorphism in genes regulating neuroplasticity, will diminish motor response to
treatment"; we will classify the participants based on the presence of subclinical
inflammation and/ or dysfunctional single nucleotide polymorphism in genes linked with
neuroplasticity.
Power calculation: Our power calculation is based on prior data in use of AIHH in healthy
humans and difference in the diaphragm motor evoked potentials with respect to sham air.
Assuming a type I error rate of 0.05, a treatment difference of 30%, and the corresponding
standard deviation of 41, we have 80% power to detect the treatment improvement of AIHH over
sham exposure given a sample size of 29. Given that in this study a combinatorial treatment
approach and no preliminary data is available for power estimation, we assume that a sample
size of 29 participants with chronic SCI will be sufficiently powered for the experiment.
